CLINICAL AND VIROLOGIC RESPONSES TO A RECOMBINANT VACCINIA HIV-1 GP160 VACCINE (HIVAC-1E)

被引：0
|
作者：
COREY, L
COLLIER, A
COOMBS, R
ARDITTI, D
HU, SL
GREENBERG, P
MCLAREN, C
MARTIN, R
DRAGAVON, J
CHALOUPKA, K
机构：
[1] UNIV WASHINGTON,SEATTLE,WA 98195
[2] BRISTOL MYERS CORP,WALLINGFORD,CT
来源：
CLINICAL RESEARCH | 1989年 / 37卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：A562 / A562
页数：1
相关论文
共 50 条
  • [41] Structural investigation of the HIV-1 envelope glycoprotein gp160 cleavage site
    Oliva, R
    Leone, M
    Falcigno, L
    D'Auria, G
    Dettin, M
    Scarinci, C
    Di Bello, C
    Paolillo, L
    CHEMISTRY-A EUROPEAN JOURNAL, 2002, 8 (06) : 1467 - 1473
  • [42] Modifying the HIV-1 env gp160 gene to improve pDNA vaccine-elicited cell-mediated immune responses
    Megati, Shakuntala
    Garcia-Hand, Dorys
    Cappello, Sarah
    Roopchand, Vidia
    Masood, Amjed
    Xu, Rong
    Luckay, Amara
    Chong, Siew-Yen
    Rosati, Margherita
    Sackitey, Solomon
    Weiner, David B.
    Felber, Barbara K.
    Pavlakis, George N.
    Israel, Zimra R.
    Smith, Larry R.
    Eldridge, John H.
    Sidhu, Maninder K.
    Egan, Michael A.
    VACCINE, 2008, 26 (40) : 5083 - 5094
  • [43] The extracellular processing of HIV-1 envelope glycoprotein gp160 by human plasmin
    Okumura, Y
    Yano, M
    Murakami, M
    Mori, S
    Towatari, T
    Kido, H
    FEBS LETTERS, 1999, 442 (01) : 39 - 42
  • [44] CHARACTERIZATION OF A SOLUBLE, OLIGOMERIC HIV-1 GP160 PROTEIN AS A POTENTIAL IMMUNOGEN
    VANCOTT, TC
    VEIT, SCD
    KALYANARAMAN, V
    EARL, P
    BIRX, DL
    JOURNAL OF IMMUNOLOGICAL METHODS, 1995, 183 (01) : 103 - 117
  • [45] IMMUNOGENICITY OF BACULOVIRUS DERIVED HIV-1 GP160 IN INBRED STRAINS OF MICE
    KENNEDY, RC
    WARREN, RQ
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1993, : 80 - 80
  • [46] ANTI-HIV-1 VACCINE CLINICAL-TRIAL PHASE-1 USING GP160 AS ANTIGEN
    PICARD, O
    ZAGURY, D
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1993, 6 (06): : 681 - 681
  • [47] Characterization and enhancement of the interaction between HIV-1 gp120/gp160 and MBL
    Hart, ML
    Saifuddin, M
    Spear, GT
    FASEB JOURNAL, 2001, 15 (04): : A691 - A691
  • [48] ANTIBODY FINE SPECIFICITY TO HIV-1 GP160 EPITOPES IN GROUPS OF HIV-1 INFECTED INDIVIDUALS AND CORRELATION WITH CLINICAL-DISEASE PROGRESSION
    WONG, MT
    WARREN, RQ
    ANDERSON, SA
    DOLAN, MJ
    MELCHER, GP
    BOSWELL, RN
    KENNEDY, RC
    JOURNAL OF IMMUNOLOGY, 1993, 150 (08): : A241 - A241
  • [49] EFFECTS OF ADJUVANTS AND MULTIPLE ANTIGEN PEPTIDES ON HUMORAL AND CELLULAR IMMUNE-RESPONSES TO GP160 OF HIV-1
    LEVI, M
    RUDEN, U
    BIRX, D
    LOOMIS, L
    REDFIELD, R
    LOVGREN, K
    AKERBLOM, L
    SANDSTROM, E
    WAHREN, B
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1993, 6 (08): : 855 - 864
  • [50] NEUTRALIZING ANTIBODIES AGAINST HIV-1 BRU AND SF2 ISOLATES GENERATED IN MICE IMMUNIZED WITH RECOMBINANT VACCINIA VIRUS EXPRESSING HIV-1 (BRU) ENVELOPE GLYCOPROTEINS AND BOOSTED WITH HOMOLOGOUS GP160
    HU, SL
    KLANIECKI, J
    DYKERS, T
    SRIDHAR, P
    TRAVIS, BM
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1991, 7 (07) : 615 - 620
12345